|Product Overview:||Recombinant Human VEGFA, Met1-Arg191, was produced in Sf 9 (baculovirus)-derived in an animal component free process under cGMP guidelines.|
|Form:||Lyophilized from a 0.2 μm filtered solution in HCl.|
|Bio-activity:||Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is 1-6 ng/mL.
The specific activity of recombinant human VEGF165 is approximately 1.7 x 10^3 U/μg, which is calibrated against recombinant human VEGF165 WHO Standard (NIBSC code: 02/286).
|Molecular Mass:||Predicted Molecular Mass: 19.2 (monomer) kDa
SDS-PAGE: 19-21 kDa, reducing conditions
|N-terminal Sequence Analysis:||Ala27-Pro-Met-Ala-Glu-Gly-Gly-Gly-Gln-Asn|
|Endotoxin:||<0.01 EU per 1 μg of the protein by the LAL method.|
|Purity:||>97%, by SDS-PAGE with silver staining.|
|Storage:||Avoid repeated freeze-thaw cycles.
12 months, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
|Reconstitution:||Reconstitute at 100 μg/mL in sterile PBS. Alternatively, reconstitute at 500 μg/mL in sterile 4 mM HCl.|
|Quality Statement:||Our GMP proteins are produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.|
|Shipping:||The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.|
|Gene Name:||VEGFA vascular endothelial growth factor A [ Homo sapiens ]|
|Synonyms:||VEGFA; vascular endothelial growth factor A; vascular endothelial growth factor , VEGF; VEGF A; VPF|